Tuesday, February 15, 2011 9:56:17 AM
Neuro-Biotech Corp (USOTC:MRES)
Intraday Stock Chart
Today : Tuesday 15 February 2011
Click Here for more Neuro-Biotech Corp Charts.
Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES). Dr. Claude Poulin CEO is pleased to announce to its shareholders that the board of directors have voted to accept the 15 cent offer. Full details will be provided to shareholders at closing of market February 15, 2011.
For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com
FORWARD LOOKING STATEMENTS
This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements. Neuro-Biotech Corp. Dr. Claude Poulin 41 61 500 05 16 info@neuro-agora.com www.neuro-biotechcorp.com
SOURCE Neuro-Biotech Corp.
Recent MRES News
- M2Bio Sciences Appoints Adrian J. Maizey, Accomplished CEO and Financial Expert, to Advisory Board • InvestorsHub NewsWire • 07/19/2023 01:18:56 PM
- M2Bio Sciences Unveils an Exciting Line of Purple, White, and Green Teas from Kenya, Offering Extraordinary Health and Medicinal Benefits • InvestorsHub NewsWire • 07/14/2023 12:52:00 PM
- M2Bio Sciences Unveils Explainer Video Showcasing Groundbreaking NFTs and Altcoins for Drug Discovery, Revolutionizing Investment Access • InvestorsHub NewsWire • 07/06/2023 01:38:23 PM
- Institute of Biomedical Research Announces Application for Name Change and New Ticker Symbol in Anticipation of Future M&A Activities and Senior Listing • InvestorsHub NewsWire • 07/05/2023 02:04:17 PM
- M2Bio Sciences Enters into Letter of Intent to Acquire Crypto Exchange JDAX • InvestorsHub NewsWire • 06/26/2023 12:45:19 PM
- M2Bio Sciences Establishes Research Chair at The University of Pretoria for Phytomedicines • InvestorsHub NewsWire • 06/16/2023 12:30:00 PM
- M2Enviro Expands R&D Efforts to Explore Diverse Classes of Mycelium Composite Materials for Commercialization • InvestorsHub NewsWire • 06/14/2023 12:00:00 PM
- Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions • InvestorsHub NewsWire • 06/07/2023 02:06:41 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM